Background: Cirrhosis is a diffuse injury in the liver characterized by fibrosis and change in normal liver architecture into structurally abnormal nodules. Eventually hepatocytes are destroyed and replaced by fibrous tissue. Portal hypertension is one of the clinical manifestations of liver cirrhosis. Portal hypertension occurs when there is an increase in portal venous pressure and is diagnosed when the hepatic venous pressure gradient (HVPG) is >5mmHg. Non-Selective Βeta-Blockers (NSBB) such as propranolol have been used as a treatment option for portal hypertension patients with hepatic cirrhosis since 1981. Propranolol, which is a β1 and β2 adrenergic receptor antagonist, induces a decreased cardiac output and splanchnic vasoconstriction.
Objective: Describe the patterns of propranolol use in hepatic cirrhosis patients at dr.Iskak Tulungagung Regional General Hospital
Method: Descriptive observational study with retrospective data collection in the period 1 January to 31 December 2022 in hepatic cirrhosis patients.
Results & Conclusions: There were 60 patients who met the inclusion criteria. Single propranolol was used in 60 patients (100%). The most common usage pattern was propranolol (3x10mg) po in 21 patients (31%). There were 6 switching patterns and the most common was switching from propranolol (2x10mg) po to propranolol (3x10mg) po in 2 patients (3%)
